Published in Drug Week, February 29th, 2008
"Inhibition of CYP3A4 markedly increases bioavailability and increases the risk of an adverse drug reaction (ADR). Many drugs are known to have CYP3A4-blocking activity. This study was performed to investigate whether the concomitant use of a CYP3A4...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2008-02-29)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.